Dorsey & Whitney Trust CO LLC Acquires New Stake in DexCom, Inc. $DXCM

Dorsey & Whitney Trust CO LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 3,204 shares of the medical device company’s stock, valued at approximately $280,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Andra AP fonden acquired a new position in shares of DexCom during the second quarter worth about $26,000. Zions Bancorporation National Association UT acquired a new stake in DexCom in the first quarter valued at about $27,000. Anderson Financial Strategies LLC purchased a new stake in shares of DexCom in the first quarter valued at approximately $37,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the second quarter worth $45,000. Finally, Atlantic Union Bankshares Corp purchased a new position in DexCom in the second quarter worth $70,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DXCM shares. UBS Group lowered their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Barclays set a $80.00 target price on shares of DexCom and gave the stock an “equal weight” rating in a research report on Monday, November 3rd. Sanford C. Bernstein reiterated an “outperform” rating and set a $84.00 price target on shares of DexCom in a research report on Monday, November 3rd. Morgan Stanley decreased their price target on DexCom from $89.00 to $63.00 and set an “equal weight” rating on the stock in a research note on Monday, November 10th. Finally, The Goldman Sachs Group dropped their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $87.62.

Insider Buying and Selling

In other news, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The shares were bought at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the sale, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 9,999 shares of company stock valued at $619,391. Company insiders own 0.32% of the company’s stock.

DexCom Stock Down 0.7%

Shares of NASDAQ DXCM opened at $59.73 on Thursday. The firm’s 50-day moving average is $66.17 and its two-hundred day moving average is $76.90. The company has a market capitalization of $23.30 billion, a PE ratio of 41.48, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the firm posted $0.45 EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.